

Peer-reviewed journal articles featuring Fortrea oncologists published 2020-2024



Fortrea is proud to support our sponsors with a team of over 60 oncologists committed to navigating the complexities of oncology clinical research and maximizing the impact of their product to the current global therapeutic landscape. With support spanning translational research and early phase development through product launch and post-marketing studies, our team members help guide clinical development planning, establish target product profiles, perform feasibility and risk assessment and provide program-level medical oversight. This collaborative approach can result in co-authorship of peer-reviewed journal articles based on projects we've supported. They also have contributed to industry knowledge via articles about their own collaborative and academic work.

Full list of published journals:

2024	
Number	Authors, Title, Journal
2024.1	Mankan AK, Mankan N, de las Heras B, Ramkissoon SH, Bodriagova O, Vidal L, Grande E, Saini KS. Bladder cancer, loss of Y-chromosome, and new opportunities for immunotherapy. <i>Advances in Therapy</i> . January 2024. https://doi.org/10.1007/s12325-023-02758-w
2024.2	Demetriou D, Lockhat Z, Brzozowski L, Saini KS, Dlamini Z, Hull R. The Convergence of Radiology and Genomics: Advancing Breast Cancer Diagnosis with Radiogenomics. <i>Cancers</i> . March 2024. https://www.mdpi.com/2072-6694/16/5/1076
2024.3	Nesline MK, Subbiah V, Previs RA, Strickland KC, Ko H, DePietro P, Biorn MD, Cooper M, Wu N, Conroy J, Pabla S, Zhang S, Wallen ZD, Sathyan P, Saini KS, Eisenberg M, Caveney B, Severson EA, Ramkissoon S. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer. <i>Oncology & Therapy</i> . March 2024. https://link.springer.com/article/10.1007/s40487-024-00270-x
2024.4	Vidal L, Dlamini Z, Qian S, Rishi P, Karmo M, Joglekar N, Abedin S, Previs RA, Orbegosa C, Joshi C, Azim H, Karkaria H, Harris M, Mehrotra R, Berraondo M, Werutski G, Gupta S, Niikura N, Chico I, Saini KS. Equitable Inclusion of Diverse Populations in Oncology Clinical Trials: Deterrents and Drivers. <i>ESMO Open</i> . May 2024. https://www.esmoopen.com/article/S2059-7029(24)01141-4/fulltext
2024.5	Mankan AK, Shankar A, Limaye S, Ajaikumar BS, Nachane P, Singh N, Dawkhar S, Batra U, Bhosekar A, Ganguly S, Gawli P, Debnath K, Padalalu V, Reddy P, Sundaramoorthi S, Naveen KK, Bondarde S, Kumar P, Davis S, Ramkissoon S, Chacko RT, Vidal L, Chico I, Hegedus A, Gupta S, Saini KS. Cancer Trials Ecosystem in India – Ready for Prime Time? <i>JCO Global Oncology</i> . June 2024. https://ascopubs.org/doi/full/10.1200/GO.23.00405
2024.6	Wallen ZD, Ko H, Nesline MK, Hastings SB, Strickland KC, Previs RA, Zhang S, Pabla S, Conroy J, Jackson JB, Saini KS, Jensen TJ, Eisenberg M, Caveney B, Sathyan P, Severson EA, Ramkissoon SH. Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer. <i>Frontiers in Immunology</i> . June 2024. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1413956/full
2024.7	Perrone F, Pecci F, Maffezzoli M, Giudice GC, Cognigni V, Mazzaschi G, Cantini L, Santamaria L, Paoloni F, Rocchi MBL, Coriano M, Quaini F, Tiseo M, Saini KS, Berardi R, Buti S. Differential impact of lipid profile according to NLR status in patients with advanced cancer treated with immunotherapy. <i>Immunotherapy</i> . August 2024. https://doi.org/10.1080/1750743X.2024.2377953
2024.8	Quintana A, Saini KS, Vidal L, Loibl S, Curigliano G, Schmid P, Cortes J. Use of immune checkpoint inhibitors in window-of-opportunity trials for triple negative breast cancer. <i>ESMO Open</i> , in press. August 2024.

Full list of published journals continued:

2023	
Number	Authors, Title, Journal
2023.1	Filho PN, Albuquerque C, Pilon M, Debiasi M. Immune checkpoint inhibitors in breast cancer: a narrative review. <i>Oncology & Therapy</i> . March 2023. https://doi.org/10.1007/s40487-023-00224-9
2023.2	McDonald K, Seltzer E, Lu M, Gaisenband SD, Fletcher C, McLeroth P, Saini KS. Quantifying the Impact of the COVID-19 Pandemic on Clinical Trial Enrollment Screening Rates Over Time in 37 Countries. <i>Trials</i> . April 2023. https://doi.org/10.1186/s13063-023-07277-1
2023.3	Salifu I, Singh N, Berraondo M, Remon J, Salifu S, Severson E, Quintana A, Peiró S, Ramkissoon S, Vidal L, Chico I, Saini KS. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> . April 2023. https://doi.org/10.1016/j.ctarc.2023.100713
2023.4	Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Vecchia A, Di Giacomo AM, Festino L, Cortinovia D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study. <i>Journal of National Cancer Institutes</i> . April 2023. https://doi.org/10.1093/jnci/djad061
2023.5	Severson E, Achyut BR, Nesline M, Pabla S, Previs RA, Kannan G, Chenn A, Zhang S, Klein R, Conroy J, Sausen M, Sathyan P, Saini KS, Ghosh A, Jensen TJ, Reddy P, Ramkissoon SH. RNA sequencing identifies novel NRG1-fusions in solid tumors that lack co-occurring oncogenic drivers. <i>The Journal of Molecular Diagnostics</i> . May 2023. https://doi.org/10.1016/j.jmoldx.2023.03.011
2023.6	Czajka-Francuz P, Prendes M, Mankan A, Quintana A, Pabla S, Ramkissoon SH, Jensen TJ, Peiró S, Severson EA, Achyut BR, Vidal L, Poelman M, Saini KS. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. <i>Frontiers in Oncology</i> . June 2023. https://doi.org/10.3389/fonc.2023.1200646
2023.7	Mankan AK, Czajka-Francuz P, Prendes M, Ramanan S, Koziej M, Vidal L, Saini KS. Intracellular DNA sensing by neutrophils and amplification of the innate immune response. <i>Frontiers in Immunology</i> . June 2023. https://doi.org/10.3389/fimmu.2023.1208137
2023.8	Bodriagova O, Previs RA, Gaba L, Shankar A, Vidal L, Saini KS. Recent advances in gynecological malignancies: Focus on ASCO 2023. <i>Oncology & Therapy</i> . September 2023. https://doi.org/10.1007/s40487-023-00244-5
2023.9	Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, Lo Russo G, Galli G, Proto C, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R. Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study. <i>Oncologist</i> . October 2023. https://doi.org/10.1093/oncolo/oyad273

Full list of published journals continued:

Number	Authors, Title, Journal
2023.10	Dlamini Z, Molefi T, Khanyile R, Mkhabele M, Damane B, Kokoua A, Bida M, Saini KS, Chauke-Malinga N, Luvhengo TE, Hull R. From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa. <i>Oncology & Therapy</i> . November 2023. https://doi.org/10.1007/s40487-023-00248-1
2023.11	Ko H, Previs R, Strickland K, Caveney B, Chiruzzi C, Eisenberg M, Severson E, Ramkissoon S, Saini KS. Is HER2-low a new clinical entity or merely a biomarker for an antibody drug conjugate? <i>Oncology & Therapy</i> . November 2023. https://doi.org/10.1007/s40487-023-00249-0
2023.12	Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, Prasad CP, Singh A, Bhat AA, Macha MA, Benali M, Saini KS, Previs RA, Saini D, Saha D, Dutta P, Bhatnagar AR, Darwal M, Shankar A, Singh M. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. <i>Vaccines</i> . November 2023. https://doi.org/10.3390/vaccines11111721
2023.13	Cantini L, Trapani D, Guidi L, Bielo LB, Scafetta R, Koziej M, Vidal L, Saini KS, Curigliano G. Neoadjuvant Therapy in Hormone Receptor-Positive/HER2-Negative Breast Cancer. <i>Cancer Treatment Reviews</i> . December 2023. https://doi.org/10.1016/j.ctrv.2023.102669

2022	
Number	Authors, Title, Journal
2022.1	Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. <i>Journal of Immunotherapy for Cancer</i> . January 2022. https://doi.org/10.1136/jitc-2021-003231
2022.2	Saini KS, Svane IM, Juan M, Barlesi F, André F. Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges. <i>Annals of Oncology</i> . January 2022. https://doi.org/10.1016/j.annonc.2021.09.020
2022.3	de las Heras B, Daehnke A, Saini KS, Harris M, Morrison K, Aguilo A, Chico I, Vidal L, Myles J, Marcus R. Decentralized Clinical Trials in Oncology: Perspectives of Oncologists and Patients. <i>Digital Health</i> . May 2022. https://doi.org/10.1177/20552076221099997





Full list of published journals continued:

2021	
Number	Authors, Title, Journal
2021.1	Saini KS, Twelves C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. <i>British Journal of Cancer</i> . April 2021. https://www.nature.com/articles/s41416-021-01319-8
2021.2	Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, Curigliano G, de Azambuja E, Lambertini M. Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology & Therapy</i> . May 2021. https://doi.org/10.1007/s40487-021-00157-1
2021.3	Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M; ALTTO Steering Committee and Investigators (Hilbers F, El-Abed S, Balta V, Schurmans C, Rosa DD, Saini KS, Filho OM, McConnell R, Paterson V, Campbell C, McFadden E, Paterson E, Kassab G). Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> . May 2021. https://doi.org/10.1016/j.ejca.2021.01.053
2021.4	Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion in Biologic Therapy</i> . June 2021. https://doi.org/10.1080/14712598.2021.1936494
2021.5	Tagliamento M, Agostinetti E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, Punie K, Westphalen CB, Morgan G, Pronzato P, Del Mastro L, Poggio F, Lambertini M. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis. <i>Critical Reviews in Oncology and Hematology</i> . July 2021. https://doi.org/10.1016/j.critrevonc.2021.103365
2021.6	de Las Heras B, Bouyoucef-Cherchalli D, Reeve L, Reichl A, Mandarino D, Flach S, Vidal L, van Brummelen EMJ, Steeghs N. Healthy volunteers in first-in-human oncology drug development for small molecules. <i>British Journal of Clinical Pharmacology</i> . September 2021. https://doi.org/10.1111/bcp.15092

Full list of published journals continued:

2020	
Number	Authors, Title, Journal
2020.1	Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Effect of the COVID-19 pandemic on cancer treatment and research. <i>Lancet Haematology</i> . June 2020. https://doi.org/10.1016/S2352-3026(20)30123-X
2020.2	Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> . June 2020. https://doi.org/10.1038/s41416-020-0948-x
2020.3	de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, Romano M, Capelan M, Prasad R, Pattu P, Massard C, Portera C, Saini ML, Singh BP, Venkitaraman R, McNally R, Leone M, Grande E, Gupta S. Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. <i>Oncology & Therapy</i> . August 2020. https://doi.org/10.1007/s40487-020-00124-2
2020.4	Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A. Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> . September 2020. https://doi.org/10.1200/GO.20.00346
2020.5	Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, Curigliano G, de Azambuja E. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> . November 2020. https://doi.org/10.1016/j.ejca.2020.08.011



LEARN MORE at fortrea.com